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Fructose in the lumen of the small intestine is transported across the brush border membrane by GLUT5, then across the basolateral
membrane by GLUT2, which also transports glucose. Diets containing high fructose (HF) specifically enhance intestinal GLUT5 expression
in neonatal rats, but there is little information concerning the dietary regulation of GLUT2 expression during early development. In this study,
we perfused for 1–4 h 100 mM fructose, glucose (HG), a-methylglucose, or mannitol solutions into the jejunum of anaesthetized 20-day-old
rat pups. GLUT2 mRNA abundance increased only in HF- and HG-perfused intestines, an effect inhibited by actinomycin D but not by
cycloheximide. Bypassed (Thiry-Vella) intestinal loops were constructed, then pups were fed either HF or low-carbohydrate diets for 5 days.
GLUT2 mRNA abundance increased significantly in both bypassed and anastomosed intestines of Thiry-Vella pups fed HF. In contrast,
GLUT5 mRNA abundance increased only in the anastomosed segment. In sham-operated pups, GLUT2 and GLUT5 mRNA abundance
increased in both intestinal regions that corresponded to the bypassed and anastomosed regions of Thiry-Vella pups. SGLT1 mRNA
abundance was independent of diet and intestinal region in both Thiry-Vella and sham-operated pups. Unlike GLUT5 expression, which is
regulated at the level of transcription only by luminal fructose, GLUT2 mRNA expression is transcriptionally regulated by luminal fructose
and glucose as well as by systemic factors released during their absorption.D 2003 Elsevier Science B.V. All rights reserved.Keywords: GLUT5; Membrane; Metabolism; Nutrient; SGLT1; Transcription; Transporter1. Introduction
The prevailing model of intestinal sugar transport depicts
fructose and glucose being absorbed from the small intestinal
lumen into the cell by GLUT5 and SGLT1 located in the
brush border membrane, respectively [1]. Both sugars are
then transported from the cytosol into the blood by GLUT2
located in the basolateral membrane. Defects in SGLT1
result in glucose–galactose malabsorption [1] whereas
defects in GLUT2 result in Fanconi–Bickel syndrome, a
disorder of carbohydrate metabolism typically showing signs
of hepatomegaly secondary to glycogen accumulation, glu-
cose and galactose intolerance, fasting hypoglycemia and0005-2736/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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water, NJ 08807-2854, USA.proximal tubular nephropathy [2]. In glucose–galactose
malabsorption and Fanconi–Bickel syndrome, utilization
of fructose is normal. Interestingly, intestinal fructose mal-
absorption has not (yet) been traced to defects in GLUT5
synthesis [3]. There are other models of intestinal sugar
transport but these have remained highly controversial. One
model proposes that the presence of glucose in the intestinal
lumen activates, via SGLT1, contraction of the epithelial
cytoskeleton, thereby opening tight junctions to permit mass
transport by solvent drag through paracellular channels [4].
A more recent model proposes that a significant component
of intestinal glucose absorption is mediated by the rapid,
glucose-dependent activation and recruitment of GLUT2 to
the brushborder membrane [5]. The main arguments against
these models have been findings that glucose–galactose
malabsorption occurs in humans when SGLT1 is absent
[1,6], and that normal glucose absorption occurs in mice
when GLUT2 is absent [17].
Intestinal glucose and fructose transport are regulated by
diet, and SGLT1, GLUT5 as well as GLUT2 mRNA anded.
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drate in adults of many species [7,8]. Regulation of sugar
transport differs in neonatal mammalian intestine, primarily
because GLUT5 is not expressed or is underexpressed at
early stages of development, appearing in significant quan-
tities only after 24–30 days of age [9–12]. Work in our
laboratory documented that precocious introduction of a
high-fructose (HF) diet to early weaning rats younger than
24 day significantly enhanced fructose absorption and
GLUT5 gene expression [11,13]. Perfusion or gavage feed-
ing of fructose solutions fails to induce GLUT5 expression
in suckling rats younger than 15 days of age [14], indicating
that both GLUT5 expression and the ability to regulate
GLUT5 expression are constrained by development. Intes-
tinal glucose transport and SGLT1 mRNA levels, unlike
fructose transport and GLUT5 mRNA, are already substan-
tial before birth in mammalian small intestine but there
seems to be little or no regulation of SGLT1 expression
during early postnatal development [11,14–16].
While intestinal GLUT2 mRNA is known to be
expressed at high levels during birth [11], there has been
no study on regulatory mechanisms underlying expression
of these transporters postnatally and surprisingly, also no
study on dietary regulation of mRNA abundance. Moreover,
recent theories about GLUT2 being transiently recruited to
the intestinal brush border membrane [5] and about a
GLUT2-independent intestinal glucose transport pathway
[17] have led us to examine GLUT2 regulation in neonates,
in hopes of increasing our understanding of the regulation of
this important transporter. We therefore determined the
levels of intestinal GLUT2 mRNA during early develop-
ment, assessed regulation as a function of age and perfusion
duration, then tested the effect of various sugars on intes-
tinal GLUT2 expression. To test the hypothesis that
GLUT2, like GLUT5, is regulated only by luminal factors,
we used the Thiry-Vella surgical method to create a
bypassed loop of small intestine in pups fed diets that varied
in carbohydrate content. To test the hypothesis that luminal
carbohydrates induces the de novo synthesis of GLUT2
mRNA, we injected transcriptional and translational inhib-
itors to pups prior to intestinal perfusion and measurements
of GLUT2 mRNA abundance. When possible, we compare
dietary regulation of GLUT2 expression to that of GLUT5
or SGLT1, to illustrate major differences in patterns of
regulation of these intestinal sugar transport systems. We
also determined GLUT2 mRNA abundance in fetal and
adult humans, to demonstrate developmental differences in
expression of this transporter.2. Materials and methods
2.1. Animals and human tissue
Adult male and female Sprague–Dawley rats weighing
f 200 g were purchased from Taconic (Germantown, NY)and bred. Rats were housed in a temperature-controlled room
(22–24 jC) with a 12:12-h light–dark cycle in the research
animal facility, and allowed access to water and chow ad
libitum (Purina Mills, Richmond, IN). After the female rats
became pregnant, they were separated from the males and
carefully monitored until the pups were born. The time and
date of birth were recorded; age at birth was considered day 0.
In the study monitoring GLUT2 mRNA abundance, pups
aged 1, 10 and 21 days old as well as adults (>100-day-old)
were sacrificed and their intestine collected for Northern blot
analysis. All the procedures conducted in this study were
approved by the Institutional Animal Care and Use Commit-
tee, UMDNJ-New Jersey Medical School.
Total RNA extracted from normal human intestinal
tissues was purchased from BioChain Institute, (Hayward,
CA) and stored in our laboratory at  80 jC until analyzed.
The tissues were collected from a 37-week-old female fetus
and a 63-year-old male, respectively.
2.2. Perfusion model
The intestinal perfusion procedure was conducted fol-
lowing the method of Jiang and Ferraris [18]. Briefly, rat
pups (21-day-old, not starved) were anesthetized by intra-
peritoneal injection of ketamine cocktail (20% ketamine and
12.5% xylazine in 0.9% NaCl, 0.2 ml/100 g i.p.). The
abdominal cavity was opened, and the small intestine with
intact blood vessels and nerve connections was exposed.
About 5 cm distal to the ligament of Treitz, a small incision
was made, and a catheter was inserted into the lumen and
then secured with surgical thread. A plastic tube (Tygon,
0.8-mm ID) was catheterized into the ileum 10 cm from the
ileocecal valve. After the contents were flushed, the small
intestine (100 mM sugar in Ringer, 37 jC) was continuously
perfused with sugar solution at a rate of 30 ml/h at 37 jC
using a peristaltic pump. The composition of the perfusion
solution was as follows (in mM): 78 NaCl, 4.7 KCl,
CaCl22.5H2O, 1.2 MgSO4, 19 NaHCO3, 2.2 KH2CO3,
and 100 mM sugar. The concentration of sugar was based
on previous findings that the magnitude and time course of
enhancement of GLUT5 mRNA abundance and fructose
transport rates with 100 mM fructose perfusion were the
same as those observed when pups were fed 65% fructose
pellets [18]. Moreover, this concentration resulted in a rapid
induction of GLUT2 and GLUT5 expression within hours
after start of perfusion [18]. Rat pups were kept under
continuous anesthesia by adding ketamine cocktail into
the abdominal cavity every 15–20 min. Body and perfusion
solution temperatures as monitored by mini-temperature
probes were maintained at 37 jC by heat lamps and water
baths, respectively.
2.3. Effect of different sugars on GLUT2 mRNA expression
To test the effect of perfusion duration on GLUT2
expression, pups were perfused with HF or HG for 1, 4 or
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with the dam. To test the effects of different sugars, pups
were randomly divided into two groups. In the first group,
pups were perfused with 100 mM fructose (HF), glucose
(HG) or mannitol for 1 h, while some littermates were not
perfused. In the second group, pups were perfused with HF,
HG, high mannitol, or 100 mM high methyl-a-D-glucose for
4 h. Unfortunately, some pups perfused with high mannitol
did not survive perfusion for 4 h. At the end of each
perfusion, the small intestine was gently isolated and
flushed with ice-cold Krebs–Ringer–bicarbonate (KRB)
solution. The small intestine in the unperfused group was
also flushed with ice-cold KRB solution. About 10 cm of
jejunum approximately 10 cm from the ligament of Treitz
was quickly frozen in liquid nitrogen for later Northern blot
analysis.
2.4. Effect of actinomycin D on GLUT2 mRNA expression
Briefly, pups were injected with the transcription inhib-
itor actinomycin D (2.4 mg/kg body wt i.p.) or vehicle (10%
ethanol in PBS) 12 h before intestinal perfusion. One group
of pups was perfused with sugar solutions for 1 h and
another group for 4 h. Each group was further divided into
six subgroups (n = 5–6 pups/subgroup), as follows. Pups
were injected with (1) vehicle and perfused with HF, (2)
actinomycin D and perfused with HF, (3) vehicle and
perfused with HG, (4) actinomycin D and perfused with
HG, (5) vehicle but not perfused, and (6) actinomycin D but
not perfused and remained with the dam.
2.5. Effect of cycloheximide on GLUT2 mRNA expression
Briefly, mid-weaning rats were injected with the protein
synthesis inhibitor cycloheximide (2.5 mg/kg body wt i.p.)
or vehicle (0.6% ethanol in PBS) about 1 h before intestinal
perfusion for 4 h. Rats were divided into the following four
groups (n= 5–6 pups). Rats were injected with (1) vehicle
and perfused with HF, (2) cycloheximide and perfused with
HF, (3) vehicle and perfused with HG, and (4) cyclohex-
imide and perfused with HG.
2.6. The role of luminal or systemic factors regulating
GLUT2 mRNA expression
We analyzed RNA samples collected from previous
experiments on the role of systemic and luminal factors
regulating GLUT5 expression [16].
2.6.1. Surgery
Pups were kept with the dams in the same cage until 19–
20 days of age, and starved for 12 h before surgery. Rat pups
were anesthetized using a ketamine cocktail (i.p.), and a
ventral midline incision was made under sterile conditions.
A 12-cm segment of jejunum about 8 cm distal to the
ligament of Treitz was resected then brought to the surfaceas a double jejunostomy, with its vascular stalk left intact.
The remaining bowel was anastomosed end-to-end. Sham-
operated animals were treated similar to those with bypassed
loops, except that instead of constructing a bypassed loop,
the excised segment was reimplanted back to the remaining
intestine with double anastomoses. All the pups were
provided 2-ml subcutaneous injections of lactated saline
immediately after surgery and were allowed to recover
overnight without food. After recovery, the pups were
further divided into two groups to be fed either HF or
low-carbohydrate (LC) pellets.
2.6.2. Diet
The HF and LC diets (Dyets, Bethlehem, PA) were
isocaloric and supplied in pellet form. The HF diet consisted
of 65% fructose, 20% casein, and 0.3% DL-methionine. The
LC diet contained 10% glucose, 74.2% casein, and 1.1% DL-
methionine. The other components including 5% corn oil,
5% cellulose, 3.5% salt mix, 1% vitamin mix, and 0.2%
choline bitartrate are the same in the two diets. We chose
fructose as carbohydrate source instead of glucose, because
we wanted to determine the substrate-induced responses of
GLUT2, which transports both glucose and fructose, and
those of GLUT5, which transports only fructose. GLUT5
results have been described in an earlier paper [16] and
summarized in the discussion.
In the bypassed loop study, 10 cm of bypassed or
anastomosed intestine was cut out and rinsed with ice-cold
KRB solution, and then was snap-frozen in liquid nitrogen.
All tissues were subsequently stored at  80 jC for later
RNA isolation and Northern blots.
2.7. RNA isolation
For the actinomycin D, cycloheximide, and Thiry-Vella
loop experiments, total RNA extraction and poly(A)+ RNA
isolation methods were as described previously [11,18]. For
all other tissues, total RNA isolation was done using a
RNeasy Midi Kit (QIAGEN, Valencia, CA) following the
manufacturer’s instructions.
2.8. Northern blot analysis
The Northern blot analysis was processed as follows: 30
Ag of total RNA or 20 Ag of poly(A)+ RNA were subjected
to 1% agarose–6% formaldehyde electrophoresis and then
transferred to a nitrocellulose membrane by capillary action.
cDNA probes of rat GLUT2, GLUT5, SGLT1 and 18S were
labeled with [32P]dCTP using a random primer labeling kit
(RTS RadPrime DNA labeling system, GIBCO BRL, Gai-
thersburg, MD). Probes for rat GLUT5 and 18S were gifts
from Drs. C. Burant and M. Lee while those for SGLT1 and
GLUT2 were generated by PCR as described previously
[18,19]. After the membranes were hybridized with the
above probes for f 16 h, the membranes were exposed
to an X-ray film for f 4–72 h depending on blot density.
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to radioactivity in the membrane, each X-ray film was
checked for saturation. Quantification was performed using
a densitometry system (IS-1000 Digital Imaging System,
Alpha Innotech).
2.9. Statistical analysis
Data are presented as meansF S.E.M. A one-, two- or
three-way ANOVA (STATVIEW, Abacus Concepts, Ber-
keley, CA) was first used to determine the significance of
the difference of relative mRNA abundance among groups
with different treatments. If there was a significant differ-
ence, Fisher’s PLSD test was used to determine the
particular effect that caused that difference. Unpaired
Student’s t-test was used to determine the difference
between HF and HG groups, or drug-treated and untreated
groups. Paired Student’s t-test was used to determine the
difference in mRNA expression between the remnant and
by-passed intestine. P < 0.05 was considered statistically
significant.3. Results
3.1. Developmental appearance and substrate regulation of
GLUT2
Intestinal GLUT2 mRNA abundance was already sig-
nificant in rats within 24 h after birth (Fig. 1A). Levels of
GLUT2 mRNA essentially remain the same through theFig. 1. Northern blots showing changes in abundance of rat (A) and human
(B) GLUT2 mRNA in the small intestine. 18S rRNA was used as loading
and transfer control. D1, 10, 21 = rat pups from two litters sacrificed at 1,
10, and 21 days of age, respectively. Only one set of human results could be
presented because the RNA from a second set was of poor quality.
However, the second set of human samples seemed to indicate similar
results as that shown here (similar levels of GLUT2 mRNA for fetal and
adult).
Fig. 2. The effect of perfusion duration (1, 4, and 8 h) on GLUT2 (A),
GLUT5 (B), and SGLT1 (C) mRNA abundance. UN, unperfused; HG and
HF= perfused with 100 mM glucose and fructose solutions, respectively.
Bars are meansF S.E. (n= 7–8). In the 1 h group, levels of GLUT2 mRNA
in all pups were initially normalized to 18S rRNA, then the normalized
GLUT2 mRNA abundance in intestines of pups perfused with HF or HG
was expressed relative to that in intestines of unperfused pups (normalized
density = 100%). A similar normalization method was used in the 4 and 8 h
groups. Different letters indicate significant differences among treatments.
GLUT2 mRNA abundance increased with glucose and fructose perfusion
while GLUT5 increased only with fructose perfusion. Perfusion had no
effect on SGLT1 mRNA abundance.late suckling (10 days of age), mid-weaning (21 days), and
adult stages. In humans, the expression of GLUT2 mRNA
in fetal and adult normal small intestines was also similar
(Fig. 1B).
Glucose and fructose perfusion enhanced GLUT2 ex-
pression (P= 0.01) (Fig. 2), but increasing the duration of
perfusion had no effect on GLUT2 mRNA abundance
(P= 0.36 by two-way ANOVA). This suggests that the
GLUT2 response may be near maximal after 1 h of sugar
Fig. 3. The effect of actinomycin D on the expression of GLUT2 mRNA in
the small intestine of neonatal rats. (A) The representative Northern Blot of
GLUT2 mRNA in the small intestines perfused with (+) or without ( )
actinomycin D (Act-D) for 1 and 4 h. 18S rRNA was the loading and
transfer control. (B) and (C) show the effect of actinomycin D on mean
abundance of GLUT2 mRNA after 1 and 4 h perfusion, respectively. Bars
are meansF S.E. (n= 5–7). The ratio of GLUT2 mRNA abundance to 18S
rRNA abundance in unperfused (UN) intestine from pups without ( )
actinomycin D was designated as 100%, and ratios in other groups were
normalized to this ratio. Different letters indicate significant differences
among treatments.
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with duration (P= 0.05 by two-way ANOVA) and fructose
perfusion (P < 0.0001). Both duration (P= 0.15) and perfu-
sion solution (P= 0.08) had no effect on SGLT1 mRNA
abundance. For GLUT2, GLUT5, and SGLT1, there was no
interaction between duration and perfusion solution (P
values z 0.20).
Perfusion of HG and HF for 1 and 4 h markedly increased
(1 h, P= 0.005; 4 h, P= 0.02 by one-way ANOVA) levels of
GLUT2 mRNA compared to those of intestines perfused
with high mannitol or high methyl-a-D-glucose solutions,
and of unperfused intestines (data not shown). In contrast,
only perfusion of HF solutions increased GLUT5 mRNA
expression (1 h, P= 0.0002; 4 h, P= 0.005 by one-way
ANOVA, data not shown). SGLT1 mRNA abundance was
independent of perfusion solution (P= 0.40, data not
shown).
3.2. Effect of transcription and translation inhibitors
As in Fig. 2, GLUT2 mRNA abundance increased in
intestines perfused with HG and HF for 1 h (P= 0.0004,
Fig. 3). Injecting rats with actinomycin D prior to perfu-
sion inhibits the HG- and HF-induced increase in GLUT2
mRNA abundance. This suggests that substrate-stimulated
induction of GLUT2 transcription occurs mainly within 1
h. The effect of actinomycin D was specific to the glucose
and fructose stimulation of GLUT2 mRNA abundance,
because actinomycin D had no effect on GLUT2 mRNA
levels in unperfused littermates. Similar results were
obtained when perfusion duration was lengthened to 4 h
after the initial injection of actinomycin D (P= 0.04,
Fig. 3).
Injecting cycloheximide prior to HG or HF perfusion had
no effect on GLUT2 mRNA abundance (P= 0.44, data not
shown).
3.3. Role of luminal and systemic factors in GLUT2
regulation
By three way ANOVA, there was no significant effect of
surgery (P= 0.27, sham-operated vs. bypassed loop) but
there were significant effects of diet (P < 0.0001, fructose
vs. LC) and intestinal region (P= 0.04, bypassed vs. anas-
tomosed) on GLUT2 mRNA abundance (Fig. 4A,B).
Although there are striking differences between bypassed
and anastomosed regions in Thiry-Vella pups in GLUT2
mRNA abundance, the P value is underestimated, because
the ‘‘bypassed’’ and ‘‘anastomosed’’ regions in the sham-
operated pups are actually continuous and hence have
similar mRNA levels.
In sham-operated pups fed LC, GLUT2 mRNA abun-
dance in the double-anastomosed reimplanted segment was
the same as that in the rest of the intestine (the intestinal
segment equivalent to the remnant intestine in Thiry-Vella
pups). In sham-operated pups fed HF pellets, both segmentsalso had similar levels of GLUT2 mRNA. However,
GLUT2 mRNA abundance in HF pups were >3 higher
than that in LC pups. The anastomosed region of Thiry-
Vella pups fed HF had 4 greater GLUT2 mRNA abun-
dance than the same region in Thiry-Vella pups fed LC.
Likewise, the bypassed loops of those fed HF had over 2
greater mRNA abundance than the bypassed loops of those
fed LC. It is interesting to note that regardless of the diet of
Thiry-Vella pups, GLUT2 mRNA abundance tended to be
greater in the bypassed compared to that in the anastomosed
loops.
Fig. 4. The effect of luminal fructose on the expression of GLUT2 and
SGLT1 mRNA in the surgically bypassed small intestine of neonatal rats.
(A) The representative Northern blot of GLUT2 and SGLT1 mRNA in the
anastomosed small intestine (SI) and bypassed loop (LP) of pups subjected
to Thiry-Vella surgery and in the same intestinal regions of littermates
subjected to sham surgery. Pups were fed either HF or LC diets for 5 days
after surgery and before being killed. The effect of luminal fructose on
mean abundance of GLUT2 (B) and SGLT1 (C) mRNA. Bars are
meansF S.E. (n = 6–9). The ratio of GLUT2 and SGLT1 mRNA
abundance to 18S rRNA abundance in the small intestine of sham-operated
rat fed LC was designated as 100%, and ratios in other groups were
normalized to this ratio. Different letters indicate significant differences
among treatments.
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(Fig. 4A,C; P= 0.29 by three way ANOVA), diet (P= 0.28),
and intestinal region (P= 0.25).4. Discussion
4.1. Substrate-dependent regulation of GLUT2 mRNA
abundance in neonatal rats
The pattern of GLUT2 regulation during development is
markedly different from that of GLUT5, the focus of mostof our laboratory’s efforts for many years [20]. Unlike
GLUT5 mRNA that has been determined by us and many
others to be conspicuously expressed in low quantities until
completion of weaning [10,11,21], GLUT2 mRNA is
already present in the fetal human and neonatal rat small
intestine in quantities similar to those in adults. In fact, in
prenatal rats, GLUT2 mRNA begins to be expressed on day
16 after conception, before the intestinal villi are evident
[22].
Although recent studies by one laboratory have sug-
gested the presence of GLUT2 in the brush border mem-
brane [5], GLUT2 has been widely accepted as the
basolateral transporter shared by and responsible for the
exit of glucose, fructose, and galactose from the intestinal
cell to the blood [7,23]. Recent studies in human small
intestine localizes this transporter to the basolateral mem-
brane [6]. Because intestinal cells need a source of energy
during prenatal development, the teleological explanation
for its early appearance is that GLUT2 may provide
nutrients to the developing intestine by absorbing nutrients
from the blood into the cell. In contrast, the other intestinal
facilitative sugar transporter, GLUT5, is specialized for
absorbing fructose, a nutrient that is not normally encoun-
tered either luminally or vascularly until after weaning when
mammals consume plant-derived carbohydrates. Hence,
GLUT5 appears late during development in almost all
mammals studied so far [20].
GLUT2 mRNA expression in neonatal rat intestine is
specifically regulated by its substrates glucose and fructose,
since mannitol (a nonabsorbable and nonmetabolizable
sugar), a-methyl-D-glucose (a nonmetabolizable sugar that
is a substrate of SGLT1 but not GLUT2), and LC diets do
not enhance GLUT2 expression. In adult rats, basolateral
glucose transport rates, cytochalasin B binding (an indicator
of GLUT2 protein abundance in the membrane), and
GLUT2 mRNA abundance in the small intestine have also
been known to vary with dietary glucose, fructose, and
carbohydrate levels [24–26]. Hence, dietary or luminal
regulation of GLUT2 expression in neonatal intestine is
similar to regulation of GLUT2 in adult intestine. Dietary
regulation of GLUT2, which responds to luminal carbohy-
drate, glucose, and fructose levels, is markedly different
from that of GLUT5, which only responds to luminal
fructose. Likewise, regulation of GLUT2 and GLUT5 differ
in the human intestinal cancer cell line Caco2 [27].
4.2. Regulation by vascular or luminal substrates of GLUT2
Although GLUT2 is basolateral and therefore not in
direct contact with luminal glucose or fructose, luminal
sugars can still stimulate GLUT2 expression and activity
[24–26]. GLUT2 is also regulated by vascular or systemic
increases in glucose or fructose concentrations, as in vivo
vascular infusions of glucose produced an increase in
glucose transport across basolateral membrane vesicles
and in GLUT2 protein abundance of rat and sheep small
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methylfructose increases GLUT2 activity in the basolateral
membrane [30]. Our findings indicate that GLUT2 expres-
sion is enhanced by both luminal and systemic factors
because GLUT2 mRNA abundance increases in the anas-
tomosed region as well as in the bypassed loop, which has
no access to luminal fructose, of pups fed high levels of
dietary fructose. HF feeding in rats increases plasma fruc-
tose concentrations [31]. However, we do not know whether
an increase in plasma fructose itself or another signal/s
secondarily released by hyperfructosemia is responsible
for upregulating GLUT2 expression in the small intestine.
There are many factors like glycaemia, insulin, glucagon,
and other hormones that may be the systemic factors
affecting GLUT2 gene expression. For example, abnormal
perturbations in the plasma concentrations of glucose,
insulin, or glucagon as those occurring in diabetes increase
the abundance GLUT2 mRNA in the small intestine [32,33].
In contrast to that of GLUT2, GLUT5 mRNA abundance
increased only in the anastomosed region of Thiry-Vella
pups fed HF [16], indicating that GLUT5 responds only to
luminal and not vascular factors. It is not clear to us why
GLUT2 mRNA expression is consistently greater in the
bypassed loop than in the anastomosed segment from Thiry-
Vella rats fed either HF or LC diets. This finding suggests
that a feedback or compensatory mechanism may arise from
an empty intestinal lumen emulating ‘‘starvation’’ condi-
tions, and that the cells attempt to enhance the expression of
GLUT2 in order to absorb more sugars from the blood.
4.3. The substrate-induced increase in GLUT2 mRNA is
regulated at the transcriptional level
The effect of glucose and fructose on GLUT2 mRNA
abundance can be prevented by a priori administration of
actinomycin D. We ensured that the dosage of actinomycin
D was effective by attempting several dosages [18] and by
determining that the diet-induced increases in expression of
immediate early genes c-fos and c-Jun were also prevented
by actinomycin D [34]. The effect of actinomycin D on
preventing substrate-induced increases in intestinal GLUT2
mRNA abundance was specific, as it did not affect the
mRNA abundance of non-inducible genes like SGLT1 [18].
Hence, glucose and fructose likely stimulate the transcrip-
tion of GLUT2 just as fructose alone stimulates transcription
of GLUT5 [18]. In the liver, the glucose-stimulated in-
creases in GLUT2 mRNA abundance are due not to stabi-
lization of GLUT2 transcripts but rather to a direct effect of
glucose on GLUT2 transcription [35]. Cycloheximide, a
translation inhibitor, did not block the glucose- or fructose-
enhanced expression of GLUT2 mRNA. This suggests that
synthesis of new proteins is not necessary for increases in
GLUT2 mRNA abundance. Cycloheximide also did not
block the fructose-induced increase in GLUT5 mRNA
abundance, but did prevent the increase in GLUT5 activity
[18]. These effects of cycloheximide on GLUT2 andGLUT5 mRNA are specific, because SGLT1 mRNA abun-
dance was not affected.
In this paper, we demonstrated that GLUT2 expression in
neonatal rat small intestine is rapidly induced by its substrates
fructose and glucose, and that regulation is transcriptional,
involving both systemic and luminal factors. Consumption of
high carbohydrate diets is therefore expected to result in rapid
and dramatic increases in GLUT2 expression, eventually
resulting in increased transport capacity of the intestine for
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